Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to ...

Study Rundown: Many patients with localized, high-risk soft tissue sarcomas develop metastatic disease. Immunotherapy, such ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...